Want to see BIIB full AI Analyst Report?
Earnings Data
Report Date
Jul 29, 2026Before Open (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
3.2Last Year’s EPS
5.47Same Quarter Last Year
Moderate Buy
Based on 26 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call highlighted multiple clear commercial and pipeline strengths — notably strong EPS growth, $851M in growth‑product revenue (up 12%), LEQEMBI growth (up 74% YoY) and a robust development cadence with key readouts and program milestones — alongside planned investments and a strategic acquisition (Apellis) expected to be accretive in 2027. Near‑term headwinds include timing/inventory lumpiness, material acquired IPR&D charges impacting near‑term EPS, increased R&D/SG&A investments and regulatory/clinical binary risks on pioneering programs. On balance, management portrayed confidence in execution, cash flow and future growth optionality.Company Guidance
Strong Q1 Financial Performance
Total revenue of $2.5 billion, up 2% year-over-year; GAAP diluted EPS $2.15, up 31% YoY; non-GAAP diluted EPS $3.57, up 18% YoY; generated $594 million of free cash flow; exited quarter with $4.7 billion cash and marketable securities and $1.5 billion net debt.
Growth Products Momentum
Growth products generated $851 million in Q1, up 12% year-over-year, and for the first quarter produced more revenue than the remaining MS portfolio.
LEQEMBI Adoption and Persistence
LEQEMBI market revenue $168 million in Q1, up 74% YoY; continues to lead by total patient share in the U.S., Japan and China; real-world persistence ~80% at 18 months and ~70% at 2 years; PDUFA for IQLIK initiation scheduled for May 24 to potentially improve convenience and competitive profile.
SKYCLARYS Global Launch Progress
SKYCLARYS global revenue $151 million in Q1, representing 22% growth YoY; now available in 35 countries with continuing ex-U.S. demand growth and sequential patient uptake outside the U.S.
SPINRAZA High-Dose Approvals and Early Uptake
High-dose SPINRAZA approved in the U.S., Japan and Europe with early patient starts already reported; positive anecdotal reports of switches/back-switches and early conversion rates (Germany reference ~20% conversion in early launch).
Pipeline Progress and Readout Calendar
Notable development progress including durable 1-year benefit data for Salanersen in previously gene‑therapy treated children, first patient dosed in pivotal STELLA-1, positive Phase II data for Litifilimab in SLE/CLE, and a multiyear registrational data flow beginning in 2026 with multiple Phase III readouts planned through the decade.
Strategic Acquisition Opportunity (Apellis)
Proposed Apellis acquisition (SYFOVRE, Empaveli) expected to expand immunology/rare disease portfolio, materially increase EPS outlook and be accretive to non-GAAP EPS in 2027; company plans to fund with ~$3.6 billion cash plus $2 billion in borrowings and expects to repay the new debt by end of 2027.
Felzartamab & Nephrology Expansion
Acquired China rights for felzartamab (TJ Bio transaction) to strengthen nephrology franchise; management cites growing conviction in felzartamab and expects Phase III readouts (AMR) and a meaningful commercial opportunity in IgAN/nephrology.
Maintained Cost Discipline While Investing
Approximately $1.1 billion of non-GAAP core operating expenses in Q1 while increasing investments in late‑stage programs and launches; management underscores disciplined cost posture alongside targeted R&D and commercial spending.
Robust Cash Flow and Capital Allocation Flexibility
Generated $594 million FCF in the quarter and emphasized ability to support business investments and M&A while targeting deleveraging post‑transaction (Apellis) via expected cash flow generation.
BIIB Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
BIIB Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Apr 29, 2026 | $183.38 | $194.38 | +6.00% |
Feb 06, 2026 | $185.36 | $201.18 | +8.53% |
Oct 30, 2025 | $147.86 | $149.61 | +1.18% |
Jul 31, 2025 | $126.64 | $128.00 | +1.07% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Biogen Inc. (BIIB) report earnings?
Biogen Inc. (BIIB) is schdueled to report earning on Jul 29, 2026, Before Open (Confirmed).
What is Biogen Inc. (BIIB) earnings time?
Biogen Inc. (BIIB) earnings time is at Jul 29, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is BIIB EPS forecast?
BIIB EPS forecast for the fiscal quarter 2026 (Q2) is 3.2.
